Hamilton Thorne Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Kate Torchilin

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

Jul 29

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Aug 15

Announcing: Hamilton Thorne (CVE:HTL) Stock Soared An Exciting 590% In The Last Five Years

Jan 19

Are Insiders Selling Hamilton Thorne Ltd. (CVE:HTL) Stock?

Jan 06

What Did Hamilton Thorne's (CVE:HTL) CEO Take Home Last Year?

Dec 24

We Think Hamilton Thorne (CVE:HTL) Can Stay On Top Of Its Debt

Dec 12

Is It Time To Consider Buying Hamilton Thorne Ltd. (CVE:HTL)?

Nov 30

A Look At The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)

Nov 17

CEO

Kate Torchilin

less than a year

Tenure

Dr. Ekaterina Torchilin PhD, MBA, also known as Kate, is President, Chief Executive Officer and Director of Hamilton Thorne Ltd. from January 15, 2024. She served as Chief Executive Officer of Biocell Cent...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Wolf	Executive Chairman	13.2yrs	US$1.27m	2.13% CA$ 7.4m
Francesco Fragasso	Chief Financial Officer	2.2yrs	US$476.26k	0.025% CA$ 85.0k
Justin Jaundoo	Vice President of Corporate Development	no data	US$395.95k	0.021% CA$ 71.7k
Brett Fulton	Senior VP & GM of HT Inc.	3.5yrs	US$391.30k	geen gegevens
Julia Heinzmann	Managing Director of Gynemed	no data	US$247.11k	geen gegevens
Ekaterina Torchilin	President	less than a year	geen gegevens	geen gegevens
Thomas Kenny	Senior Vice President Global Operations & Sustaining Engineering and Management Rep	no data	US$165.49k	geen gegevens
Kimberly Marolda	Director of HR	no data	geen gegevens	geen gegevens
Eric Dorman	President of Embryotech Laboratories Inc	no data	geen gegevens	geen gegevens
Fabian Sell	Chief Executive Officer of Gynemed	no data	US$282.51k	geen gegevens
Dan Ryan	Finance Controller	no data	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van HTL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Wolf	Executive Chairman	13.2yrs	US$1.27m	2.13% CA$ 7.4m
Ekaterina Torchilin	President	less than a year	geen gegevens	geen gegevens
Robert Potter	Lead Independent Director	15.1yrs	US$113.50k	0.32% CA$ 1.1m
Daniel Thorne	Independent Director	15.1yrs	US$66.00k	13.15% CA$ 45.5m
Bruno Maruzzo	Independent Director	17.7yrs	US$103.50k	0.17% CA$ 583.1k
Karen Firestone	Independent Director	2.8yrs	US$113.50k	0.060% CA$ 207.7k
David Sable	Independent Director	7.8yrs	US$66.00k	0.095% CA$ 329.2k
Marc Robinson	Independent Director	3.8yrs	US$66.00k	0.062% CA$ 213.5k
Meg Spencer	Chairman Emeritus	2.3yrs	geen gegevens	geen gegevens
Cynthia Hudson	Member of Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Feng Han	Independent Director	3.8yrs	US$113.50k	0.064% CA$ 219.9k
Thomas Ebner	Member of Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HTL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Hamilton Thorne Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024

Chair, President & CEO exercised options to buy CA$102k worth of stock.

Chair, President & CEO recently sold CA$101k worth of stock

Hamilton Thorne Ltd. Announces Passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer

High number of new directors

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.003 loss in 2Q 2023)

Hamilton Thorne Ltd. to Report Q2, 2024 Results on Aug 14, 2024

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

New minor risk - Share price stability

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hamilton Thorne Ltd. to Report Q1, 2024 Results on May 14, 2024

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$0.004 loss per share (vs US$0.013 profit in FY 2022)

Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024

Hamilton Thorne Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024

New major risk - Revenue and earnings growth

Hamilton Thorne Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Hamilton Thorne Ltd. (TSX:HTL) agreed to acquire Gynetics Medical Products N.V. for an enterprise value of €18.3 million.

Consensus EPS estimates increase by 80%

New minor risk - Shareholder dilution

Hamilton Thorne Ltd.(TSXV:HTL) dropped from S&P/TSX Venture Composite Index

Consensus EPS estimates fall by 80%

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.002 profit in 2Q 2022)

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Hamilton Thorne Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Consensus EPS estimates fall by 50%

First quarter 2023 earnings released: EPS: US$0.001 (vs US$0.004 in 1Q 2022)

Hamilton Thorne Ltd. to Report Q1, 2023 Results on May 15, 2023

Chair, President & CEO exercised options to buy CA$102k worth of stock.

Chair, President & CEO recently sold CA$101k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued

Consensus EPS estimates increase by 17%

Now 20% undervalued after recent price drop

Hamilton Thorne Ltd. Announces Passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer

Now 21% undervalued after recent price drop

Hamilton Thorne Ltd. (TSXV:HTL) agreed to acquire Microptic, S.L.

Consensus EPS estimates fall by 33%

Hamilton Thorne Ltd. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.001 (vs US$0.002 in 3Q 2021)

High number of new directors

Hamilton Thorne Ltd. to Report Nine Months, 2022 Results on Nov 22, 2022

Consensus EPS estimates fall by 23%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q2, 2022 Results on Aug 23, 2022

Hamilton Thorne Ltd. Announces CFO Changes

Chair, President exercised options to buy CA$86k worth of stock.

Chair, President exercised options to buy CA$886k worth of stock.

Consensus EPS estimates fall by 20%

At CA$1.40, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q1, 2022 Results on May 19, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Hamilton Thorne Ltd., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Chair, President exercised options to buy CA$293k worth of stock.

Hamilton Thorne Ltd. to Report Q4, 2021 Results on Apr 07, 2022

Is Hamilton Thorne (CVE:HTL) Using Too Much Debt?

High number of new directors

President recently bought CA$75k worth of stock

President recently sold CA$635k worth of stock

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Safely

Second quarter 2021 earnings released: EPS US$0.003 (vs US$0.004 loss in 2Q 2020)

Hamilton Thorne Ltd. (TSXV:HTL) acquired IVFTECH ApS and K4 Technology ApS for an enterprise value of approximately DKK 50 million ($8 million).

President exercised options to buy CA$115k worth of stock.

Should You Think About Buying Hamilton Thorne Ltd. (CVE:HTL) Now?

Consensus EPS estimates increase to US$0.028

First quarter 2021 earnings released: EPS US$0.006 (vs US$0.001 in 1Q 2020)

Hamilton Thorne (CVE:HTL) Will Be Hoping To Turn Its Returns On Capital Around